Horizons in pharmacologic intervention in allergic contact dermatitis.
The treatment of allergic contact dermatitis remains a major challenge. Current management strategies consist of elimination of the allergen when possible and therapy for symptoms with topical or systemic corticosteroids. With increasing exposure of the human skin to environmental antigens and haptens, more selective treatment options are needed. Advances in the elucidation of the skin immune system and of the cellular and molecular events in immunologic processes may allow targeted methods of controlling delayed hypersensitivity reactions. This review focuses on mechanisms of established therapeutic agents and new developments, such as FK 506 (tacrolimus), pentoxifylline, and vitamin D3 derivative, for suppression of any phase of allergic contact dermatitis.
Funk
J O
JO
Department of Dermatology, School of Medicine, University of California, San Francisco.
Maibach
H I
HI
D000485:Allergens; D002762:Cholecalciferol / Q000627:therapeutic use; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010431:Pentoxifylline / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000485:Allergens; D002762:Cholecalciferol; D010431:Pentoxifylline; D016559:Tacrolimus